Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.65 |
| ▸ | MEN1 | O00255 | 11/20 | 0.65 |
| ▸ | MIF | P14174 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | ITGA1 | P56199 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808980 | 0.89 | KMT2A (0.80) | KMT2AMEN1PKMPOLBITGA1 | |
| SCHEMBL14420811 | 0.89 | KMT2A (0.64) | KMT2AMEN1MIFPKMPOLB | |
| SCHEMBL4094983 | 0.89 | MEN1 (0.66) | KMT2AMEN1PKMMAPT | |
| SCHEMBL14075283 | 0.88 | MAPT (0.77) | KMT2AMEN1MIFPKMMAPT | |
| SCHEMBL6720181 | 0.85 | MEN1 (0.85) | KMT2AMEN1PKMMAPTPOLB | |
| SCHEMBL7448446 | 0.81 | MEN1 (0.72) | KMT2AMEN1MIFPKMMAPT | |
| SCHEMBL6721013 | 0.80 | CASP3 (0.74) | KMT2AMEN1PKMMAPTPOLB | |
| SCHEMBL6349464 | 0.80 | MEN1 (0.70) | KMT2AMEN1PKMMAPTITGA1 | |
| SCHEMBL27770303 | 0.79 | KDM4E (0.68) | KMT2AMEN1POLB | |
| SCHEMBL7449687 | 0.79 | MEN1 (0.64) | KMT2AMEN1MIFPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| EP-1758571-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM Pharma A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005115374-A1 | CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE | 7TM PHARMA A/S (DK) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | NR1H2, NR1H3, HRH2 | KMT2A 2570/4885MEN1 2859/4885MIF 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.